Effects of multiple-dose esomeprazole and pantoprazole on diazepam pharmacokinetic profile and pharmacodynamic effects on cognitive and psychomotor function in healthy volunteers

Abstract

A randomized, double-blind, 2-way crossover trial of 24 healthy volunteers investigated the influence of esomeprazole (CAS 119141-88-7) and pantoprazole (CAS 102625-70-7), both 1 × 40 mg orally for 11 days, on the pharmacokinetics and pharmacodynamics of diazepam (CAS 439-14-5). Single-dose intravenous diazepam 0.1 mg/kg was administered on day 6. Blood sampling for pharmacokinetic assessment was conducted 0–120 h post diazepam application and data were analyzed using a model-independent approach and ANOVA. Pharmacodynamic parameters were assessed by an oculodynamic test and auditory evoked potentials 0–10 h post diazepam application. Data were analyzed using a linear mixed regression model. The AUC of diazepam was increased by 28.0%, C_max by 31.4% and t_1/2 by 41.1% in the esomeprazole vs. pantoprazole group. Myogenic parameters such as angular velocity of saccadic eye movements and complex choice reaction time were impaired with esomeprazole when compared to pantoprazole after diazepam administration (P < 0.0028) at 4–6 h. The sedation parameter micro-sleep doubled (2.6 vs. 1.1%; P < 0.0073). No differences in auditory evoked potentials were observed. In conclusion, it cannot be ruled out that a relevant pharmacodynamic interaction between diazepam and esomeprazole may occur when both drugs are concomitantly administered. Pantoprazole may provide a higher safety profile.

Key words

Benzodiazepines - Diazepam - Esomeprazole - Pantoprazole - Pharmacodynamics - Pharmacokinetics - Proton pump inhibitors

• References

• 1 Cheer SM, Prakash A, Faulds D, Lamb HM. Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders. Drugs. 2003; 63 (1) 101-33
• 2 Scott LJ, Dunn CJ, Mallarkey G, Sharpe M. Esomeprazole: a review of its use in the management of acid-related disorders. Drugs. 2002; 62 (10) 1503-38
• 3 Blume H, Donath F, Warnke A, Schug BS. Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Saf. 2006; 29: 769-84
• 4 Gerson LB, Triadafilopoulos G. Proton pump inhibitors and their drug interactions: an evidence-based approach. Eur J Gastroenterol Hepatol. 2001; 13: 611-6
• 5 Simon WA. Pantoprazole – which cytochrome P450 isozymes are involved in its biotransformation?. Gut. 1995; 37 (02) A135
• 6 Andersson T, Hassan-Alin M, Hasselgren G, Rohss K, Weidolf L. Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet. 2001; 40 (6) 411-26
• 7 Gerson LB, Triadafilopoulos G. Proton pump inhibitors and their drug interactions: an evidence-based approach. Eur J Gastroenterol Hepatol. 2001; 13 (5) 611-6
• 8 Andersson T, Hassan-Alin M, Hasselgren G, Rohss K. Drug interaction studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet. 2001; 40 (7) 523-37
• 9 Andersson T, Miners JO, Veronese ME, Tassaneeyakul W, Tassaneeyakul W, Meyer UA et al. Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br J Clin Pharmacol. 1993; Dec 36 (6) 521-30
• 10 Tucker GT. The interaction of proton pump inhibitors with cytochromes P450. Aliment Pharmacol Ther. 1994; 8 (01) 33-8
• 11 Andersson T, Andren K, Cederberg C, Edvardsson G, Heggelund A, Lundborg P. Effect of omeprazole and cimetidine on plasma diazepam levels. Eur J Clin Pharmacol. 1990; 39 (1) 51-4
• 12 Gugler R, Jensen JC. Omeprazole inhibits oxidative drug metabolism. Studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro. Gastroenterology. 1985; 89 (6) 1235-41
• 13 Gugler R, Jensen JC. Drugs other than H2-receptor antagonists as clinically important inhibitors of drug metabolism in vivo. Pharmacol Ther. 1987; 33 (1) 133-7
• 14 Gugler R, Hartmann M, Rudi J, Brod I, Huber R, Steinijans VW et al. Lack of pharmacokinetic interaction of pantoprazole with diazepam inman. Br J Clin Pharmacol. 1996; Aug 42 (2) 249-52
• 15 Schaffler K, Kauert G, Wauschkuhn CH, Klausnitzer W. Longitudinal study on pharmacodynamics and pharmacokinetics of acute, steady-state and withdrawn quazepam. Arzneimittelforschung. 1989; 39 (2) 276-83
• 16 Schaffler K, Klausnitzer W. Single dose study on buspirone versus diazepam in volunteers. Monitoring psychomotor performance via oculomotor, choice reaction and electromyographic parameters. Arzneimittelforschung. 1988; 38 (2) 282-7
• 17 Schaffler K. Electrophysiological and psychophysiological data concerning different benzodiazepine-anxiolytics. Psychiatrie. 1985; 2: 24-8
• 18 Schaffler K. Vigilance study using electro-oculographic and electroencephalographic methods after acute budipine administration in healthy subjects. In: Poewe W, Stern G. editors. Clinical experiences with budipine in parkinson therapy. Berlin: Springer Verlag; 1985: 194-202
• 19 Schaffler K, Klausnitzer W. Acute effects of two dosages of orally administered midazolam on psychomotor performance in healthy volunteers. Arzneimittelforschung 1989; 39 (3) 395-8
• 20 Schaffler K, Hadler D, Stark M. Dose-effect relationship of idebenone in an ex-perimental cerebral deficit model. Pilot study in healthy young volunteers with piracetamas reference drug. Arzneimittelforschung 1998; 48 (7) 720-6
• 21 Schaffler K, Arnold H, Hörmann E. The action of clobazam and diazepamoncomputer-assisted tests ofmuscle activity: oculomotor effects. Drug Dev Res. 1982; S1 (01) 39-46
• 22 Puchler K, Schaffler K, Plenker A. The comparative effects of single and multiple doses of RS-8359, moclobemide and placebo on psychomotor function in healthy subjects. Int Clin Psychopharmacol. 1997; 12 (05) S17-S23
• 23 Putt M, Chinchilli VM. A mixed effects model for the analysis of repeated measures cross-over studies. Stat Med. 1999; 18 (22): 3037-58
• 24 Steinijans VW, Hartmann M, Huber R, Radtke HW. Lack of pharmacokinetic interaction as an equivalence problem. Int J Clin Pharmacol Ther Toxicol. 1991; 29 (8) 323-8
• 25 Jung F, Richardson TH, Raucy JL, Johnson EF. Diazepam metabolismby cDNA-expressed human 2C P450s: identification of P4502C18 and P4502C19 as low K(M) diazepam N-demethylases. Drug Metab Dispos. 1997; 25: 133-9
• 26 Ono S, Hatanaka T, Miyazawa S, Tsutsui M, Aoyama T, Gonzalez FJ et al. Human liver microsomal diazepamme- tabolism using cDNA-expressed cytochrome P450s: role of CYP2B6, 2C19 and the 3A subfamily. Xenobiotica. 1996; 26: 1155-66
• 27 Zomorodi K, Houston JB. Diazepam-omeprazole inhibition interaction: an in vitro investigation using human liver microsomes. Br J Clin Pharmacol. 1996; 42: 157-62
• 28 Yasumori T, Nagata K, Yang SK, Chen LS, Murayama N, Yamazoe Y et al. Cytochrome P450 mediated metabolism of diazepam in human and rat: involvement of human CYP2C in N-demethylation in the substrate concentration-dependent manner. Pharmacogenetics. 1993; 3: 291-301
• 29 Andersson T, Miners JO, Veronese ME, Birkett DJ. Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms. Br J Clin Pharmacol. 1994; 38: 131-7
• 30 Ishizaki T, Chiba K, Manabe K, Koyama E, Hayashi M, Yasuda S et al. Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of S-mephenytoin 4’-hydroxylation. Clin Pharmacol Ther. 1995; 58: 155-64
• 31 Wan J, Xia H, He N, Lu YQ, Zhou HH. The elimination of diazepam in Chinese subjects is dependent on the mephenytoin oxidation phenotype. Br J Clin Pharmacol. 1996; 42: 471-4
• 32 Zhang YA, Reviriego J, Lou YQ, Sjöqvist F, Bertilsson L. Diazepam metabolism in native Chinese poor and extensive hydroxylators of S-mephenytoin: interethnic differences in comparison with white subjects. Clin Pharmacol Ther. 1990; 48: 496-502
• 33 Andersson T, Cederberg C, Edvardsson G, Heggelund A, Lundborg P. Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole. Clin Pharmacol Ther. 1990; 47: 79-85
• 34 Bertilsson L, Henthorn TK, Sanz E, Tybring G, Säwe J, Villén T. Importance of genetic factors in the regulation of diazepammetabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype. Clin Pharmacol Ther. 1989; 45: 348-55
• 35 Schwender D, Klasing S, Madler C, Poppel E, Peter K. Effects of benzodiazepines on mid-latency auditory evoked potentials. Can J Anaesth. 1993; 40 (12) 1148-54
• 36 Scaife JC, Groves J, Langley RW, Bradshaw CM, Szabadi E. Sensitivity of late-latency auditory and somatosensory evoked potentials to threat of electric shock and the sedative drugs diazepam and diphenhydramine in human volunteers. J Psychopharmacol. 2006; 20 (4) 485-95
• 37 Abduljawad KA, Langley RW, Bradshaw CM, Szabadi E. Effects of clonidine and diazepam on prepulse inhibition of the acoustic startle response and the N1/P2 auditory evoked potential in man. J Psychopharmacol. 2001; 15 (4) 237-42
• 38 Saari TI, Laine K, Bertilsson L, Neuvonen PJ, Olkkola KT. Voriconazole and fluconazole increase the exposure to oral diazepam. Eur J Clin Pharmacol. 2007; 63: 941-9
• 39 Ahonen J, Olkkola KT, Neuvonen PJ. The effect of the antimycotic itraconazole on the pharmacokinetics and pharmacodynamics of diazepam. Fundam Clin Pharmacol. 1996; 10: 314-8
• 40 Madhusoodanan S, Bogunovic OJ. Safety of benzodiazepines in the geriatric population. Expert Opin Drug Saf. 2004; 3 (5) 485-93